Deciphex, Dublin, Ireland-based provider of pathology software and services, raised €3.9 million in a Series B extension funding round led by Seroba Life Sciences and existing Deciphex investors.
This round follows the €11.5 million round it raised in May 2022. With this, the total Series B funding raised by the company tallies to €14.4 million.
This additional investment will allow Deciphex to continue developing its innovative products and services, expand its presence in the UK, Canada, the Middle East, and the US, and strengthen its position as a leader in the field of digital pathology and AI.
Donal O'Shea, CEO of Deciphex, said, "This additional investment will allow us to continue to grow and innovate, solidifying our position as a leader in the field of pathology. We are committed to helping pathologists deliver the best possible care to patients through the use of cutting-edge technology."
Deciphex offers a range of services for clinical and research pathology, including its Patholytix platform for research pathology. Its Diagnexia clinical service provides remote subspecialty pathology services.
The company's solutions have already been adopted by leading research organizations and pharmaceutical companies, and its products are trusted by customers around the world.
Jennifer McMahon, a partner with Seroba, will join the Board of Deciphex.
Company: Deciphex Limited
Round: Series B
Funding Month: January 2023
Lead Investors: Seroba Life Sciences
Company Website: https://www.deciphex.com/
Software Category: Pathology Software
About the Company: Founded in 2017, Deciphex is a software company that focused on developing digital pathology-based software and services for clinical and research pathology. The company believes that digital pathology combined with artificial intelligence will help make pathologists work more efficiently, offering a solution to the pending challenges in supply/demand in pathology services. The company's aim is to network and accelerate the work of pathologists around the world.